Montreh Tavakkoli
Montreh Tavakkoli
Verified email at
Cited by
Cited by
Acute promyelocytic leukemia: where did we start, where are we now, and the future
CC Coombs, M Tavakkoli, MS Tallman
Blood Cancer Journal 5 (2015), e304, 2015
WUSCHEL mediates stem cell homeostasis by regulating stem cell number and patterns of cell division and differentiation of stem cell progenitors
RK Yadav, M Tavakkoli, GV Reddy
Development 137 (21), 3581-3589, 2010
A high-resolution gene expression map of the Arabidopsis shoot meristem stem cell niche
RK Yadav, M Tavakkoli, M Xie, T Girke, GV Reddy
Development 141 (13), 2735-2744, 2014
CD99 is a therapeutic target on disease stem cells in myeloid malignancies
SS Chung, WS Eng, W Hu, M Khalaj, FE Garrett-Bakelman, M Tavakkoli, ...
Science translational medicine 9 (374), eaaj2025, 2017
A Novel Paradigm Between Leukocytosis, G-CSF Secretion, Neutrophil-to-Lymphocyte Ratio, Myeloid-Derived Suppressor Cells, and Prognosis in Non-small Cell Lung Cancer
M Tavakkoli, C Wilkins, J Mones, M Mauro
Frontiers in Thoracic Oncology, 2019
Pathogenic microRNA’s in myeloid malignancies
M Khalaj, M Tavakkoli, AW Stranahan, CY Park
Frontiers in genetics 5, 110913, 2014
CD99 Is a Therapeutic Target On Disease Stem Cells In Acute Myeloid Leukemia and The Myelodysplastic Syndromes
SS Chung, M Tavakkoli, SM Devlin, CY Park
Blood 122 (21), 2891-2891, 2013
Identification of novel markers for stem-cell niche of Arabidopsis shoot apex
P Aggarwal, RK Yadav, GV Reddy
Gene Expression Patterns 10 (6), 259-264, 2010
S1563 Acute Acalculous Cholecystitis During Severe COVID-19 Hospitalizations
N Wahid, T Bhardwaj, C Borinsky, M Tavakkoli, D Wan, T Wong
Official journal of the American College of Gastroenterology| ACG 115, S794, 2020
Cutaneous Ewing sarcoma and Ewing sarcoma of the bone: distinct diseases
M Tavakkoli, L Mueller
Case Reports in Oncology 11 (3), 729-734, 2018
Do preclinical studies suggest that CD99 is a potential therapeutic target in acute myeloid leukemia and the myelodysplastic syndromes?
M Tavakkoli, SS Chung, CY Park
Expert Opinion on Therapeutic Targets 22 (5), 381-383, 2018
Acute promyelocytic leukemia: where did we start, where are we now, and the future. Blood Cancer J 5: e304
CC Coombs, M Tavakkoli, MS Tallman
Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study
N Epperla, RL Welkie, P Torka, G Shouse, R Karmali, L Shea, ...
Journal of Hematology & Oncology 16 (1), 49, 2023
Survivorship in adolescents and young adults
A Kishtagari, M Tavakkoli, J Park
Acta Haematologica 132 (3-4), 383-90, 2014
2024 Update: Advances in the risk stratification and management of large B‐cell lymphoma
M Tavakkoli, SK Barta
American Journal of Hematology 98 (11), 1791-1805, 2023
Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study
N Epperla, Q Zhao, R Karmali, P Torka, L Shea, TS Oh, ...
Blood Advances 7 (17), 5038-5046, 2023
The significance of leukocytosis in malignancies: a novel paradigm between leukocytosis, G-CSF, myeloid-derived suppressor cells and prognosis
M Tavakkoli, C Wilkins, JV Mones, MJ Mauro
Blood 132, 4944, 2018
CD99 Is a Therapeutic Target on Disease Initiating Stem Cells in Acute Myeloid Leukemia and the Myelodysplastic Syndromes
SS Chung, M Tavakkoli, VM Klimek, CY Park
Blood 124 (21), 2014
Epichaperome Abundance Predicts Response to the Epichaperome Inhibitor, PUH-71, in Acute Myeloid Leukemia
M Tavakkoli, J Kaner, S Sahil, T Taldone, S Merugu, G Chiosis, G Roboz, ...
ASH 134 (Issue Supplement_1), 2019
Targeting CD99 in T-Cell Neoplasms with Monoclonal Antibodies
M Tavakkoli, DH Lee, B Durham, SS Chung, CY Park
Blood 126 (23), 2749, 2015
The system can't perform the operation now. Try again later.
Articles 1–20